/ /

  • linkedin
  • Increase Font
  • Sharebar

    KeraLink poised for new era in corneal transplantation

    TBI rebranding focuses on increasing number of sight-saving procedures performed globally


    Rebranding rewards

    Esen K. Akpek, MD, is familiar with both KeraLink’s national and international programs and sees several benefits from the rebranding.

    “Now that KeraLink doesn’t have to worry about the musculoskeletal division, they have more time and resources to dedicate to surgeons and they’re able to listen to what the surgeons need,” said Dr. Akpek, national medical director for KeraLink and professor of ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore.

    This focus has been shown through streamlined location and delivery of tissue, as well as stronger emphasis on educational programs being offered at major ophthalmology meetings, at KeraLink facilities, and in collaboration with medical centers.

    A joint effort with the Wilmer Eye Institute’s Center of Excellence for Ophthalmic Surgical Education and Training has led to a new CME course on Descemet’s membrane endothelial keratoplasty (DMEK).

    By teaching surgeons about new instrumentation and techniques, the course will make it easier for them to convert to a procedure that, while more challenging than Descemet’s stripping endothelial keratoplasty (DSEK), has better outcomes, Dr. Akpek said.

    One KeraLink program that she sees as being particularly exciting is increasing the use of irradiated corneal tissue to treat anterior corneal problems, which make up about two-thirds of corneal transplantations performed outside of the United States.

    Irradiated corneas, which have a 2-year shelf life, could potentially save the sight of thousands of people, and KeraLink is in discussions for collaborations with eye banks in India and elsewhere to make this tissue available to those who need it the most.



    Esen Akpek, MD

    P: 410/955-7927

    E: [email protected]

    Dr. Akpek is national medical director for KeraLink.


    Douglas Furlong

    E: [email protected]

    Furlong is the organization’s president and chief executive officer.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results